Matricellular Proteins: New Molecular Targets To Prevent Heart Failure

Cardiovascular Therapeutics

Volumn 30, Issue 4, 2012, Pages

  Okamoto, Hiroshi ^a   Imanaka Yoshida, Kyoko ^b  

^a HOKKAIDO MEDICAL CENTER   (Japan)

^b MIE UNIVERSITY   (Japan)

Author keywords

Cardiac remodeling; Heart failure; Matricellular proteins; Osteopontin; Tenascin C

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; AUTOTAXIN; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH ANGIOGENIC INDUCER; GALECTIN; HEVIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRICELLULAR PROTEIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEONECTIN; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; TENASCIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WISP2 PROTEIN; WISP3 PROTEIN; WNT INDUCED SECRETED PROTEIN 1;

CAPILLARY; CONGESTIVE CARDIOMYOPATHY; ENZYME ACTIVITY; HEART FAILURE; HEART FUNCTION; HUMAN; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; CCN INTERCELLULAR SIGNALING PROTEINS; CELL ADHESION; EXTRACELLULAR MATRIX PROTEINS; HEART DISEASES; HEART FAILURE; HUMANS; MYOCARDIUM; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SIGNAL TRANSDUCTION; TENASCIN; VENTRICULAR REMODELING;

EID: 84856750390     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00276.x     Document Type: Review

References (119)

1. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
2. Bornstein P. Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J Cell Biol 1995;130:503-506.
3. Bornstein P, Sage EH. Matricellular proteins: Extracellular modulators of cell function. Curr Opin Cell Biol 2002;14:608-616.
4. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: Possible role during stress and remodeling. Cardiovasc Res 2004;64:24-31.
5. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010;48:504-511.
6. Schellings MW, van Almen GC, Sage EH, Heymans S. Thrombospondins in the heart: Potential functions in cardiac remodeling. J Cell Commun Signal 2009;3:201-213.
7. Tan K, Lawler J. The interaction of thrombospondins with extracellular matrix proteins. J Cell Commun Signal 2009;3:177-187.
8. Bornstein P. Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal 2009;3:189-200.
9. Kyriakides TR, Maclauchlan S. The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J Cell Commun Signal 2009;3:215-225.
10. McCurdy S, Baicu CF, Heymans S, Bradshaw AD. Cardiac extracellular matrix remodeling: Fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol 2009;48:544-549.
11. Bradshaw AD. The role of SPARC in extracellular matrix assembly. J Cell Commun Signal 2009;3:239-246.
12. Leask A, Abraham DJ. All in the CCN family: Essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006;119:4803-4810.
13. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009;41:771-783.
14. Nie J, Sage EH. SPARC functions as an inhibitor of adipogenesis. J Cell Commun Signal 2009;3:247-254.
15. Norris RA, Moreno-Rodriguez R, Hoffman S, Markwald RR. The many facets of the matricelluar protein periostin during cardiac development, remodeling, and pathophysiology. J Cell Commun Signal 2009;3:275-286.
16. Snider P, Standley KN, Wang J, Azhar M, Doetschman T, Conway SJ. Origin of cardiac fibroblasts and the role of periostin. Circ Res 2009;105:934-947.
17. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat Rev Cancer 2008;8:212-226.
18. Kubota T, Zhang Q, Wrana JL, et al. Multiple forms of SppI (secreted phosphoprotein, osteopontin) synthesized by normal and transformed rat bone cell populations: Regulation by TGF-beta. Biochem Biophys Res Commun 1989;162:1453-1459.
19. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-1061.
20. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-512.
21. Xie Z, Singh M, Singh K. Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension 2004;44:826-831.
22. Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994;145:1450-1462.
23. Williams EB, Halpert I, Wickline S, Davison G, Parks WC, Rottman JN. Osteopontin expression is increased in the heritable cardiomyopathy of Syrian hamsters. Circulation 1995;92:705-709.
24. Szalay G, Sauter M, Haberland M, et al. Osteopontin: A fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res 2009;104:851-859.
25. Singh K, Sirokman G, Communal C, et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 1999;33:663-670.
26. Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ Res 2008;102:319-327.
27. Ashizawa N, Graf K, Do YS, et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996;98:2218-2227.
28. Serlin DM, Kuang PP, Subramanian M, O'Regan A, Li X, Berman JS, Goldstein RH. Interleukin-1beta induces osteopontin expression in pulmonary fibroblasts. J Cell Biochem2006;97:519-529.
29. Xie Z, Pimental DR, Lohan S, et al. Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: Role of p42/44 mitogen-activated protein kinase and reactive oxygen species. J Cell Physiol 2001;188:132-138.
30. Nystrom T, Duner P, Hultgardh-Nilsson A. A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Exp Cell Res 2007;313:1149-1160.
31. Graf K, Do YS, Ashizawa N, et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997;96:3063-3071.
32. Subramanian V, Krishnamurthy P, Singh K, Singh M. Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice. Am J Physiol Heart Circ Physiol 2007;292:H673-H683.
33. Krishnamurthy P, Peterson JT, Subramanian V, Singh M, Singh K. Inhibition of matrix metalloproteinases improves left ventricular function in mice lacking osteopontin after myocardial infarction. Mol Cell Biochem 2009;322:53-62.
34. Collins AR, Schnee J, Wang W, et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 2004;43:1698-1705.
35. Zhao X, Johnson JN, Singh K, Singh M. Impairment of myocardial angiogenic response in the absence of osteopontin. Microcirculation 2007;14:233-240.
36. Matsui Y, Jia N, Okamoto H, et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004;43:1195-1201.
37. Kim HJ, Lee HJ, Jun JI, et al. Intracellular cleavage of osteopontin by caspase-8 modulates hypoxia/reoxygenation cell death through p53. Proc Natl Acad Sci U S A 2009;106:15326-15331.
38. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur J Heart Fail 2005;7:755-762.
39. Okamoto H. Osteopontin and cardiovascular system. Mol Cell Biochem 2007;300:1-7.
40. Soejima H, Irie A, Fukunaga T, et al. Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circ J 2007;71:1879-1884.
41. Rosenberg M, Zugck C, Nelles M, et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008;1:43-49.
42. Tamura A, Shingai M, Aso N, Hazuku T, Nasu M. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J 2003;67:742-744.
43. Suezawa C, Kusachi S, Murakami T, et al. Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: Correlation with left-ventricular volume and function. J Lab Clin Med 2005;145:33-40.
44. Zile MR, Desantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011. doi:.
45. Del Ry S, Giannessi D, Maltinti M, et al. Increased plasma levels of osteopontin are associated with activation of the renin-aldosterone system and with myocardial and coronary microvascular damage in dilated cardiomyopathy. Cytokine 2010;49:325-330.
46. Arnlöv J, Evans JC, Benjamin EJ, et al. Clinical and echocardiographic correlates of plasma osteopontin in the community: The Framingham Heart Study. Heart 2006;92:1514-1515.
47. Georgiadou P, Iliodromitis EK, Kolokathis F, et al. Plasma osteopontin as a predictor of coronary artery disease: Association with echocardiographic characteristics of atherosclerosis. Eur J Clin Invest 2010;40:288-293.
48. Francia P, Balla C, Ricotta A, et al. Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. Int J Cardiol 2010. doi:.
49. Singh M, Foster CR, Dalal S, Singh K. Role of osteopontin in heart failure associated with aging. Heart Fail Rev 2010;15:487-494.
50. Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta 2009;1793:888-892.
51. Chiquet-Ehrismann R, Chiquet M. Tenascins: Regulation and putative functions during pathological stress. J Pathol 2003;200:488-499.
52. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218:235-259.
53. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006;244:143-163.
54. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992;6:1821-1831.
55. Forsberg E, Hirsch E, Frohlich L, et al. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Natl Acad Sci U S A 1996;93:6594-6599.
56. Roth-Kleiner M, Hirsch E, Schittny JC. Fetal lungs of tenascin-C-deficient mice grow well, but branch poorly in organ culture. Am J Respir Cell Mol Biol 2004;30:360-366.
57. Ishii K, Imanaka-Yoshida K, Yoshida T, Sugimura Y. Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation. Dev Biol 2008;324:310-319.
58. El-Karef A, Yoshida T, Gabazza EC, et al. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol 2007;211:86-94.
59. Nakahara H, Gabazza EC, Fujimoto H, et al. Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol 2006;36:3334-3345.
60. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009;15:774-780.
61. Yamamoto K, Onoda K, Sawada Y, et al. Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Cardiovasc Res 2005;65:737-742.
62. Sawada Y, Onoda K, Imanaka-Yoshida K, et al. Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis. Cardiovasc Res 2007;74:366-376.
63. Imanaka-Yoshida K, Matsumoto K, Hara M, Sakakura T, Yoshida T. The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation 2003;71:291-298.
64. Ando K, Takahashi M, Yamagishi T, et al.Tenascin C may regulate the recruitment of smooth muscle cells during coronary artery development. Differentiation (in press).
65. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: Multiple roles of tenascin-C in tissue remodeling. Histol Hisopathol 2004;19:517-525.
66. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996;179:321-325.
67. Imanaka-Yoshida K, Hiroe M, Nishikawa T, et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001;81:1015-1024.
68. Sato A, Aonuma K, Imanaka-Yoshida K, et al. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006;47:2319-2325.
69. Odaka K, Uehara T, Arano Y, et al. Noninvasive detection of cardiac repair after acute myocardial infarction in rats by 111 In Fab fragment of monoclonal antibody specific for tenascin-C. Int Heart J 2008;49:481-492.
70. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 2002;197:388-394.
71. Sato M, Toyozaki T, Odaka K, et al. Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. Circulation 2002;106:1397-1402.
72. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol 2005;205:460-467.
73. Frangogiannis NG, Shimoni S, Chang SM, et al. Active interstitial remodeling: An important process in the hibernating human myocardium. J Am Coll Cardiol 2002;39:1468-1474.
74. Taki J, Inaki A, Wakabayashi H, et al. Dynamic expression of tenascin-C after myocardial ischemia and reperfusion: Assessment by 125I-anti-tenascin-C antibody imaging. J Nucl Med 2010;51:1116-1122.
75. Nishioka T, Suzuki M, Onishi K, et al. Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: Involvement of tenascin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 2007;49:261-268.
76. Tamura A, Kusachi S, Nogami K, et al. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: Distribution along margin of fibrotic lesions. Heart 1996;75:291-294.
77. Tsukada B, Terasaki F, Shimomura H, et al. High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: Expression of tenascin C as a possible marker for inflammation. Hum Pathol 2009;40:1015-1022.
78. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005;167:71-80.
79. Nishioka T, Onishi K, Shimojo N, et al. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2010;298:H1072-H1078.
80. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200:500-503.
81. Toma N, Imanaka-Yoshida K, Takeuchi T, et al. Tenascin-C coated on platinum coils for acceleration of organization of cavities and reduction of lumen size in a rat aneurysm model. J Neurosurg 2005;103:681-686.
82. Ballard VL, Sharma A, Duignan I, et al. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J 2006;20:717-719.
83. Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009;11:119-129.
84. Kanzaki Y, Terasaki F, Okabe M, et al. Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy. Jpn Circ J 2001;65:797-802.
85. Terasaki F, Okamoto H, Onishi K, et al. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007;71:327-330.
86. Fujimoto N, Onishi K, Sato A, et al. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Card Fail 2009;15:898-905.
87. Franz M, Berndt A, Altendorf-Hofmann A, et al. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009;11:1057-1062.
88. Hessel M, Steendijk P, den Adel B, Schutte C, Van Der Laarse A. Pressure overload-induced right ventricular failure is associated with re-expression of myocardial tenascin-C and elevated plasma tenascin-C levels. Cell Physiol Biochem 2009;24:201-210.
89. Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008;27:589-596.
90. Tanaka H, El-Karef A, Kaito M, et al. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int 2006;26:311-318.
91. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 2003;111:487-495.
92. Schellings MW, Vanhoutte D, Swinnen M, et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med 2009;206:113-123.
93. Bradshaw AD, Baicu CF, Rentz TJ, et al. Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: Role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation 2009;119:269-280.
94. Perbal B. CCN proteins: Multifunctional signalling regulators. Lancet 2004;363:62-64.
95. Kubota S, Takigawa M. CCN family proteins and angiogenesis: From embryo to adulthood. Angiogenesis 2007;10:1-11.
96. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002;4:599-604.
97. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: New targets for antifibrotic therapy?Matrix Biol 2002;21:473-482.
98. Ivkovic S, Yoon BS, Popoff SN, et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003;130:2779-2791.
99. Matsui Y, Sadoshima J. Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: Implication for cardiac fibrosis and hypertrophy. J Mol Cell Cardiol 2004;37:477-481.
100. Koitabashi N, Arai M, Kogure S, et al. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007;49:1120-1127.
101. Koitabashi N, Arai M, Niwano K, et al. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail 2008;10:373-379.
102. Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, Lau LF. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 2002;22:8709-8720.
103. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998;93:1159-1170.
104. Malek MH, Olfert IM. Global deletion of thrombospondin-1 increases cardiac and skeletal muscle capillarity and exercise capacity in mice. Exp Physiol 2009;94:749-760.
105. Schroen B, Heymans S, Sharma U, et al. Thrombospondin-2 is essential for myocardial matrix integrity: Increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004;95:515-522.
106. Batlle M, Perez-Villa F, Lazaro A, et al. Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling. Transplant Proc 2009;41:2231-2233.
107. Frangogiannis NG, Ren G, Dewald O, et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 2005;111:2935-2942.
108. Chatila K, Ren G, Xia Y, Huebener P, Bujak M, Frangogiannis NG. The role of the thrombospondins in healing myocardial infarcts. Cardiovasc Hematol Agents Med Chem 2007;5:21-27.
109. Swinnen M, Vanhoutte D, Van Almen GC, et al. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation 2009;120:1585-1597.
110. Bastiani MJ, Harrelson AL, Snow PM, Goodman CS. Expression of fasciclin I and II glycoproteins on subsets of axon pathways during neuronal development in the grasshopper. Cell 1987;48:745-755.
111. Conway SJ, Molkentin JD. Periostin as a heterofunctional regulator of cardiac development and disease. Curr Genomics 2008;9:548-555.
112. Norris RA, Damon B, Mironov V, et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem 2007;101:695-711.
113. Snider P, Hinton RB, Moreno-Rodriguez RA, et al. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res 2008;102:752-760.
114. Niu Z, Iyer D, Conway SJ, et al. Serum response factor orchestrates nascent sarcomerogenesis and silences the biomineralization gene program in the heart. Proc Natl Acad Sci U S A 2008;105:17824-17829.
115. Stansfield WE, Andersen NM, Tang RH, Selzman CH. Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart. Ann Thorac Surg 2009;88:1916-1921.
116. Oka T, Xu J, Kaiser RA, et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res 2007;101:313-321.
117. Shimazaki M, Nakamura K, Kii I, et al. Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med 2008;205:295-303.
118. Kuhn B, del Monte F, Hajjar RJ, et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med 2007;13:962-969.
119. Lorts A, Schwanekamp JA, Elrod JW, Sargent MA, Molkentin JD. Genetic manipulation of periostin expression in the heart does not affect myocyte. Circ Res 2009;104:e1-e7.